Search

ApTOLL is the first TLR4 antagonist neuroprotectant to achieve positive efficacy endpoints in acute ischemic stroke trials, decreasing significantly mortality and long-term functional disability

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today

BCN HEALTH ha publicado el estudio 'Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care' en la revista 'Expert Review of Pharmacoeconomics & Outcomes

Amadix, IOMED and NorayBio have joined forces to develop a predictive algorithm for mass data analysis to reduce the mortality rate of this disease

The “Instituto de Investigación Biomédica de Córdoba” hosts the event, supported by “Instituto de Salud Carlos III (ISCIII)”, with the sponsorship of “Universidad Carlos III de Madrid”, Cidi Salud and

The funds are from a competitive call through the 2021 State Programme to Promote Scientific-Technical Research and its Transfer (formerly known as Retos Colaboración).

The Andorran biotech company is working to obtain Good Manufacturing Practices (GMP) during the first half of 2023

Jordi Xiol has been promoted to Partner after joining Ysios Capital in 2019 Ysios is also incorporating Sanifit co-founder and CEO Joan Perelló as Venture Partner

BCN HEALTH has published 10 studies in 2022 assessing the incidence and cost of illness of different diseases in Spain.

The Galician Innovation Agency has awarded DIVERSA through the InnovaPeme program to implement its innovation plan in 2022 and 2023

Mikrobiomik aims to be the first company in the world to commercialize the first biologic medicine based on intestinal microbiota, in primary or recurrent Clostridiodes difficile infection

Laminar Pharmaceuticals S.A., se complace en anunciar el reclutamiento de los primeros 45 pacientes en el estudio clínico de fase II/III en glioblastoma de nuevo diagnóstico

 Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs

NIMBLE Diagnostics, ha cerrado con éxito una ronda de financiación donde han conseguido más un millón de euros liderada por Grow Ventures junto con Namarel Ventures e Inveniam Group

Barcelona, the leader in the biotechnology and life sciences sector in Spain, will host this edition from 26 to 28 September, which is the 20th anniversary of the event.

The spin-off of IRB Barcelona, the UB and SJD has a patented technology based on peptides (small proteins) that efficiently cross biological barriers, such as the blood-brain barrier that protects the

One of the key challenges in the process of developing new bioproducts is to overcome the transition period in which a technology under development is envisaged as promising

BCN HEALTH ha publicado el estudio Hospital Incidence and Medical Costs of Female Breast Cancer in Spain: A Retrospective Multicenter Study ' en la revista 'Current Cancer Therapy Reviews'

The science and technology company Merck has awarded the Merck Chair Award to the best works of the Master's Degree in Management of Biotechnology Companies in Health

R&D is at the heart of Almirall's strategy

6º Sachs Annual Neuroscience Innovation Forum 12º Annual LifeSci Advisors Corporate Access Event 41º Annual J.P. Morgan Healthcare Conference Invest Securities Biomed Forum 2023